In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ART (Advanced Research Technologies) gains imaging biomarker from Alerion

This article was originally published in Clinica

Executive Summary

Canadian imaging company ART (Advanced Research Technologies) is now able to offer biomarkers and contrast media to users of its preclinical and clinical imaging devices, following the acquisition of US imaging agents developer Alerion Biomedical. The move not only provides ART with a new stream of recurring revenues, it also gives the firm access to the $5bn global biomarker and radiopharmaceutical market.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts